For the Inventor, By the Inventor

Enter assignee name

Irving, TX, United States of America

Reata Pharmaceuticals, Inc.

USPTO Granted Patents = 61

CIPO Patents = 2

EPO Patents = 20

Trademarks = 10

Forward Citations = 1,375

where 'Filed Patents' based on already Granted Patents

where 'Inventors Filed' based on already Granted Patents

44 inventors (with patents filed for the assignee):

Xin Jiang (47 out of 55 patents)

Melean Visnick (46 out of 48 patents)

Eric Anderson (29 out of 47 patents)

4. Christopher F Bender (17 out of 17 patents)

5. Gary Louis Bolton (15 out of 29 patents)

6. Xiaofeng Liu (14 out of 15 patents)

7. Chitase Lee (12 out of 22 patents)

8. Bradley W Caprathe (12 out of 30 patents)

9. Robert M Kral, Jr (10 out of 10 patents)

10. Colin J Meyer (7 out of 9 patents)

11. William Howard Roark (7 out of 24 patents)

12. John Allen Walling (5 out of 5 patents)

13. Jack Greiner (5 out of 5 patents)

14. Stephen S Szucs (5 out of 7 patents)

15. Martha R Hotema (4 out of 4 patents)

61 patents: Sort by Forward Citations

1. 12344631 - C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof (2025-07-01),

2. 12195443 - Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (2025-01-14),

3. 12060340 - Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith (2024-08-13),

4. 11993574 - Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma (2024-05-28),

5. 11827664 - Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway (2023-11-28),

6. 11814338 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2023-11-14),

7. 11584775 - C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses (2023-02-21),

8. 11406648 - C17-heteroaryl derivatives of oleanolic acid and methods of use thereof (2022-08-09),

9. 11401294 - Co-crystal forms of a novobiocin analog and proline (2022-08-02),

10. 11292781 - Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (2022-04-05),

11. 11192852 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2021-12-07),

12. 11091430 - Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 (2021-08-17),

13. 11078230 - 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof (2021-08-03),

14. 11059792 - Imidazolyl tricyclic enones as antioxidant inflammation modulators (2021-07-13),

15. 10953020 - Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof (2021-03-23),

Reata Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes innovative treatments for patients with serious or life-threatening diseases. The company primarily focuses on developing small molecule therapeutics that target difficult-to-treat diseases, including rare genetic disorders, fibrosis, and inflammation.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

61 Patents

#11 in Irving, TX

#329 in Texas

#5,699 in US

#11,483 in the World

Irving, TX, United States of America

Reata Pharmaceuticals, Inc.

Forward Citations = 1,375

44 inventors:

Xin Jiang (47 out of 55 patents)

Melean Visnick (46 out of 48 patents)

Eric Anderson (29 out of 47 patents)

4. Christopher F Bender (17 out of 17 patents)

5. Gary Louis Bolton (15 out of 29 patents)

Please report any incorrect information to support@idiyas.com

Loading…